AI trial monitors promise up to 82x ROI in oncology
A Tufts CSDD analysis of Medable's AI clinical monitoring agent finds potential ROI up to 82x and an eNPV as high as $21 million per oncology program, driven by savings from reduced site visits, faster enrollment and earlier database locks. Phase 2 ROI is about 64x, Phase 3 around 82x; direct operating savings are roughly $4.4 million (Phase 2) and $5.6 million (Phase 3). Across portfolios, the impact could reach hundreds of millions for sponsors with multiple indications, with development time shortened by about 18 weeks. Some admin savings weren’t included in the eNPV calculations.